Rezolute
RZLT
Market cap $262M

4.74 USD

-0.21

4.24%

At close Oct 17, 4:00 PM EDT

After hours

4.70

-0.04

0.84%

1 day

-4.24%

5 days

1.94%

1 month

-5.01%

3 months

2.16%

6 months

46.30%

Year to date

364.71%

1 year

383.67%

5 years

-76.88%

About: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Employees: 59

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

380% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 5

200% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 6

165% more capital invested

Capital invested by funds: $69M [Q1] → $183M (+$114M) [Q2]

100% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]

58% more funds holding

Funds holding: 33 [Q1] → 52 (+19) [Q2]

14.49% more ownership

Funds ownership: 68.24% [Q1] → 82.73% (+14.49%) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

48%

upside

Avg. target

$12.14

156%

upside

High target

$15

216%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Douglas Tsao 56% 1-year accuracy 75 / 133 met price target	195%upside $14	Buy Reiterated	27 Sept 2024
JMP Securities Jason Butler 49% 1-year accuracy 19 / 39 met price target	48%upside $7	Market Outperform Reiterated	20 Sept 2024
BTIG Julian Harrison 67% 1-year accuracy 10 / 15 met price target	216%upside $15	Buy Maintained	10 Sept 2024
HC Wainwright & Co. Douglas Tsao 56% 1-year accuracy 75 / 133 met price target	195%upside $14	Buy Reiterated	9 Sept 2024
Guggenheim Debjit Chattopadhyay 70% 1-year accuracy 7 / 10 met price target	132%upside $11	Buy Initiated	27 Aug 2024

See Analyst Rankings

Financial journalist opinion

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

Zacks Investment Research

RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study

The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.

RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

Monday, the FDA removed partial clinical holds on Rezolute, Inc.'s RZLT RZ358 (ersodetug), a potential treatment for hypoglycemia (low blood sugar) caused by congenital hyperinsulinism (HI).

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

Rezolute Inc said on Monday the U.S. Food and Drug Administration has removed the partial clinical hold on its late-stage study testing its experimental treatment for low blood sugar.

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Second rare disease program with RZ358 in Phase 3 development Follows successful treatment of multiple patients with tumor hyperinsulinism under the Company's Expanded Access Program REDWOOD CITY, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for RZ358 (ersodetug) to treat hypoglycemia in patients with tumor hyperinsulinism (HI).

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Additional $6.7M in funding resulting in approximately $67M in gross proceeds Additional $6.7M in funding resulting in approximately $67M in gross proceeds

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its underwritten public offering of 11,250,000 shares of its common stock at a price to the public of $4.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,750,000 shares of its common stock at a price to the public of $3.999 per pre-funded warrant, in each case, before underwriting discounts and commissions. All of the shares and warrants in the public offering were sold by the Company.

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of its previously announced underwritten public offering of an aggregate of 11,250,000 shares of its common stock at an offering price of $4.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,750,000 shares of common stock at an offering price of $3.999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $60 million.

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof). In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock plus the shares of common stock underlying pre-funded warrants sold in connection with the public offering. The public offering is subject to market and other conditions, and there can be no assurance as to whether or when the public offering may be completed or as to the actual size or terms of the public offering. All of the shares in the public offering are being offered by the Company.

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

See News Rankings

Charts implemented using Lightweight Charts™